CN202105314U - 永电单向透药贴 - Google Patents
永电单向透药贴 Download PDFInfo
- Publication number
- CN202105314U CN202105314U CN201120201307XU CN201120201307U CN202105314U CN 202105314 U CN202105314 U CN 202105314U CN 201120201307X U CN201120201307X U CN 201120201307XU CN 201120201307 U CN201120201307 U CN 201120201307U CN 202105314 U CN202105314 U CN 202105314U
- Authority
- CN
- China
- Prior art keywords
- drug
- patch
- electret
- transdermal
- unidirectional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000013271 transdermal drug delivery Methods 0.000 title abstract description 4
- 239000003937 drug carrier Substances 0.000 claims abstract description 12
- 239000000853 adhesive Substances 0.000 claims description 12
- 230000001070 adhesive effect Effects 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 9
- 239000011505 plaster Substances 0.000 claims description 8
- 239000010409 thin film Substances 0.000 claims description 5
- 239000004745 nonwoven fabric Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 34
- 229940079593 drug Drugs 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 9
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 206010011409 Cross infection Diseases 0.000 abstract description 2
- 206010029803 Nosocomial infection Diseases 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 238000001647 drug administration Methods 0.000 abstract 2
- 239000002390 adhesive tape Substances 0.000 abstract 1
- 230000000857 drug effect Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 230000010287 polarization Effects 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 230000005684 electric field Effects 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 239000003792 electrolyte Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000037317 transdermal delivery Effects 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 201000011275 Epicondylitis Diseases 0.000 description 1
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010021333 Ileus paralytic Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000026137 Soft tissue injury Diseases 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 206010043784 Thyroiditis subacute Diseases 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 1
- 229960000385 dyclonine Drugs 0.000 description 1
- 230000005686 electrostatic field Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229960003390 magnesium sulfate Drugs 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 201000007620 paralytic ileus Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920009441 perflouroethylene propylene Polymers 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229950000845 politef Drugs 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 229930185107 quinolinone Natural products 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000007497 subacute thyroiditis Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 238000004017 vitrification Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
本实用新型公开了一种永电单向透药贴，由下到上依次包括透气胶布、驻极体膜、药物载体斑片和防粘覆盖膜。本实用新型的有益效果是：利用驻极体（永电体）薄膜实施药物促透技术，可用于人体任何体表部位，药物吸收不受消化道内pH、食物、转运时间等因素影响，避免肝脏首过效应，克服因吸收过快产生血药浓度过高而引起的不良反应。可持续控制给药速度，灵活给药，给药速度快，起效快，作用直接，疗效好，提高了生物利用度，减少总用量（全身药量1/5），无血药浓峰谷变化，无全身作用，避免毒副作用、药效稳定持久。适应范围广：化学药物、生物药物、天然药物。穿透力强，能达到较深部的组织器官。无痛、无创、方便、安全、无交叉感染。
Description
技术领域
本实用新型属于医疗器械技术领域，涉及治疗用品范畴，是一种具备透皮
给药功能的永电单向透药贴。
背景技术
透皮给药***（transdermal thrapeutic systems，transdermal drug delivery systems，简称TTS，TDDS）是指在皮肤表面给药，使药物以恒定速率（或接近恒定速率）通过皮肤，进人体循环产生全身或局部治疗作用的新给药方法。其优点体现在：药物吸收不受消化道内pH、食物、转运时间等因素影响；避免肝脏首过效应；克服因吸收过快产生血药浓度过高而引起的不良反应；可持续控制给药速度，灵活给药等。透皮给药是新发展起来的新型给药***，鉴于其更人性化的给药治疗特点以及透皮技术的进展，会具有更广阔的前景。
人的皮肤既是保护层，又是一个吸收器。利用皮肤作为药物输入体循环的门户，发挥药物的治疗作用，是对传统用药观念的重要突破，目前这一新的领域的研究非常活跃，膜—贮存型经皮给药***、骨架控释型经皮给药***、微贮库控释型经皮给药***、胶贴剂控释型经皮给药***相继问世，近期采用磁驻极体实施药物透皮技术受到医药界的极大关注。
将电介质放在电场中就会被极化。许多电介质的极化是与外电场同时存在同时消失的。也有一些电介质，受强外电场作用后其极化现象不随外电场去除而完全消失，出现极化电荷“永久”存在于电介质表面和体内的现象。这种在强外电场等因素作用下，极化并能“永久”保持极化状态的电介质，称为驻极体，又叫永电体。驻极体具有体电荷特性，即它的电荷不同于摩擦起电，既出现在驻极体表面，也存在于其内部。若把驻极体表面去掉一层，新表面仍有电荷存在；若把它切成两半，就成为两块驻极体。这一点可与永久磁体相类比。
驻极体不能像电池那样从中取出电流，然而却可以提供一个稳定的电压，因此是一个很好的直流电压源。随着对驻极体研究的深入和新材料的连续发现，它会像永磁体一样，被广泛应用。 能制成驻极体的有天然蜡、树脂、松香、磁化物、某些陶瓷、有机玻璃及许多高分子聚合物（例如K－1聚碳酸酯、聚四氟乙烯、聚全氟乙烯丙烯、聚丙烯、聚乙烯、聚酯）等。根据驻极化时所采用的物理方法，有热驻极体、光驻极体、电驻极体和磁驻极体等之分。
磁力作为药物透皮促进因素，临床已经积累了丰富的经验。磁驻极体具有特定强度和极性的静电场的持续作用，使患处组织的电解质发生相应的极化；局部微循环改善，血管通透性增加；局部氧张力减少，组织环境的减性化增强，局部Ca、K、Na、Zn等元素的含量上升，激活细胞内环磷酸腺苷（C-AMP）***，继而产生了一系列有益的生理反应，磁驻极体像其它磁性物质一样，具有良好的药物透皮促进作用。
发明内容
为解决以上技术上的不足，本实用新型提供了一种可以透皮给药，给药速度快、起效快、作用直接、疗效高的永电单向透药贴。
本实用新型是通过以下措施实现的：
本实用新型的一种永电单向透药贴，由下到上依次包括透气胶布、驻极体膜、药物载体斑片和防粘覆盖膜。
优选的，上述药物载体斑片为圆形、椭圆形或者蝴蝶形的无纺布，位于驻极体膜中心，厚度为0.3~0.5cm，直径为3~4cm。
优选的，上述驻极体膜为注磁的PE薄膜，位于透气胶布中心，直径大于药物载体斑片1cm。
优选的，上述透气胶布位于防粘覆盖膜中心，宽度为6.5cm，长度为9.5cm。
优选的，上述防粘覆盖膜宽度为7.0cm，长度为10 cm。
本实用新型的有益效果是：利用驻极体（永电体）薄膜实施药物促透技术，可用于人体任何体表部位，药物吸收不受消化道内pH、食物、转运时间等因素影响，避免肝脏首过效应，克服因吸收过快产生血药浓度过高而引起的不良反应。可持续控制给药速度，灵活给药，给药速度快，起效快，作用直接，疗效好，提高了生物利用度，减少总用量（全身药量1/5），无血药浓峰谷变化，无全身作用，避免毒副作用、药效稳定持久。适应范围广：化学药物、生物药物、天然药物。穿透力强，能达到较深部的组织器官。无痛、无创、方便、安全、无交叉感染。
附图说明
图1为本实用新型的结构示意图。
图中：1防粘覆盖膜，2透气胶布，3驻极体膜，4药物载体斑片。
具体实施方式
如图1所示，本实用新型的永电单向透药贴，由下到上依次包括透气胶布2、驻极体膜3、药物载体斑片4和防粘覆盖膜1。药物载体斑片4为圆形、椭圆形或者蝴蝶形的无纺布，位于驻极体膜3中心，厚度为0.3~0.5cm，直径为3~4cm。驻极体膜3是将PE薄膜高压注磁，温度稍高于聚合物的玻璃化温度，所用电场约0.1~1千伏每厘米，极化时间约几分钟到1小时，制成永电体薄膜。将其剪裁成形状与药物载体斑片4相同，位于透气胶布2中心，直径大于药物载体斑片1cm。透气胶布2位于防粘覆盖膜1中心，宽度为6.5cm，长度为9.5cm。防粘覆盖膜1宽度为7.0cm，长度为10 cm。清洁、灭菌后包装起来。
使用方法 ：除去防粘覆盖膜1，将药物载体斑片4置药（药物种类因疾病不同而异）后置于病灶处或疾病相关部位，再把透气胶布2连同驻极体膜3覆于其上平贴于体表即可。
例如：1.治疗甲状腺疾病（永电甲状腺治疗贴）：甲状腺机能亢进、甲状腺机能减退、亚急性甲状腺炎等。分别使用药物他巴唑、甲状腺素或强的松置于药物斑片，粘贴于颈部甲状腺部位。2.消肿止痛（永电消肿镇痛贴）：将达克罗宁、尿囊素、硫酸镁、透明质酸钠等置于药物斑片，可用于：骨科：滑膜炎、肱骨外上髁炎、颈椎病、腰椎病、慢性神经疼替代传统的封闭疗法，软组织损伤疼痛肿涨、切口疼痛肿涨。3.外科、妇产科：切口疼痛消肿、痛经治疗、乳腺增生。4.抗炎作用：将喹诺酮、甲硝唑等置于药物斑片，可用于：妇产科：***、乳腺炎。5.外科：术后切口炎症、术后切口延迟愈合。6.呼吸科：肺炎、扁桃体炎、哮喘。7.消化科：胆囊炎胆管炎、胰腺炎。8.润肠通便（永电润肠通便贴）：将组合中药置于药物斑片，可用于麻痹性肠梗阻、促进术后肠蠕动功能、恢复排气、预防肠粘连、长期卧床引起的大便排除不畅等。9.温经止痛（永电痛经止痛贴）：将组合中药置于药物斑片，可用于治疗痛经。10.其它：支气管哮喘型、小儿退热型等。
上述实施例所述是用以具体说明本专利，文中虽通过特定的术语进行说明，但不能以此限定本专利的保护范围，熟悉此技术领域的人士可在了解本专利的精神与原则后对其进行变更或修改而达到等效目的，而此等效变更和修改，皆应涵盖于权利要求范围所界定范畴内。
Claims (5)
1.一种永电单向透药贴，其特征在于：由下到上依次包括透气胶布、驻极体膜、
药物载体斑片和防粘覆盖膜。
2.根据权利要求1所述永电单向透药贴，其特征在于：所述药物载体斑片为圆形、椭圆形或者蝴蝶形的无纺布，位于驻极体膜中心，厚度为0.3~0.5cm，直径为3~4cm。
3.根据权利要求1所述永电单向透药贴，其特征在于：所述驻极体膜为注磁的PE薄膜，位于透气胶布中心，直径大于药物载体斑片1cm。
4.根据权利要求1所述永电单向透药贴，其特征在于：所述透气胶布位于防粘覆盖膜中心，宽度为6.5cm，长度为9.5cm。
5.根据权利要求1所述永电单向透药贴，其特征在于：所述防粘覆盖膜宽度为7.0cm，长度为10 cm。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201120201307XU CN202105314U (zh) | 2011-06-15 | 2011-06-15 | 永电单向透药贴 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201120201307XU CN202105314U (zh) | 2011-06-15 | 2011-06-15 | 永电单向透药贴 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN202105314U true CN202105314U (zh) | 2012-01-11 |
Family
ID=45430768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201120201307XU Expired - Lifetime CN202105314U (zh) | 2011-06-15 | 2011-06-15 | 永电单向透药贴 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN202105314U (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102895737A (zh) * | 2012-10-14 | 2013-01-30 | 徐国元 | 驻极体静电磁疗膜 |
| CN102921111A (zh) * | 2012-12-02 | 2013-02-13 | 徐国元 | 远红外静电耳压贴 |
| CN102921107A (zh) * | 2012-12-02 | 2013-02-13 | 徐国元 | 磁力静电耳压贴 |
| CN111991259A (zh) * | 2020-09-04 | 2020-11-27 | 中国科学院深圳先进技术研究院 | 一种促进植物***吸收的驻极体面膜及其制备方法 |
-
2011
- 2011-06-15 CN CN201120201307XU patent/CN202105314U/zh not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102895737A (zh) * | 2012-10-14 | 2013-01-30 | 徐国元 | 驻极体静电磁疗膜 |
| CN102921111A (zh) * | 2012-12-02 | 2013-02-13 | 徐国元 | 远红外静电耳压贴 |
| CN102921107A (zh) * | 2012-12-02 | 2013-02-13 | 徐国元 | 磁力静电耳压贴 |
| CN111991259A (zh) * | 2020-09-04 | 2020-11-27 | 中国科学院深圳先进技术研究院 | 一种促进植物***吸收的驻极体面膜及其制备方法 |
| WO2022048028A1 (zh) * | 2020-09-04 | 2022-03-10 | 中国科学院深圳先进技术研究院 | 一种促进植物***吸收的驻极体面膜及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6092469B2 (ja) | 拡張可能な創傷被覆材 | |
| CN202105314U (zh) | 永电单向透药贴 | |
| US20050131359A1 (en) | Substance delivery system | |
| CN107007927A (zh) | 一种基于电场驱动给药的微针阵列药贴及制备方法 | |
| CN108704218A (zh) | 一种皮肤无痛给药贴片 | |
| CN201431559Y (zh) | 一种理疗保健贴 | |
| CN105919728A (zh) | 一种温灸中药外敷膏贴 | |
| CN206081321U (zh) | 一种芒硝外敷袋 | |
| CN202223414U (zh) | 降温贴 | |
| CN107375994A (zh) | 一种医用凝胶创可贴产品制备方法 | |
| CN107019843A (zh) | 负压透皮给药装置 | |
| CN101274118B (zh) | 夹合自粘贴载药膜的理疗电极片及其制备方法 | |
| CN101269255A (zh) | 夹合自粘贴载药膜的理疗电极片及其制备方法 | |
| CN204671365U (zh) | 一种离子感应温感理疗贴 | |
| CN204446804U (zh) | 一种静脉留置针固定装置 | |
| CN204092615U (zh) | 一种止痛敷贴 | |
| CN114209974A (zh) | 一种石墨烯药物载体贴 | |
| CN202086668U (zh) | 战创伤镇痛贴 | |
| CN202554744U (zh) | 甲状腺永电透药治疗带 | |
| CN100588438C (zh) | 夹合自粘贴载药膜的理疗电极片及其制备方法 | |
| CN104606787A (zh) | 一种离子感应膜及其制备方法 | |
| CN201379684Y (zh) | 一种自发热脐疝压迫治疗贴 | |
| CN108211108A (zh) | 一种针对穴位持续给药的微泡贴及制备方法 | |
| CN101961281A (zh) | 一种自热式磁共振敷可贴发热体制备工艺 | |
| CN201840775U (zh) | 一种自热式磁共振敷可贴 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: QINGDAO BELLO BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: WEN XIN Effective date: 20130906 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250000 JINAN, SHANDONG PROVINCE TO: 266071 QINGDAO, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130906 Address after: 266071 Shandong Province, Qingdao city Hongkong Road No. 9 - Qingdao science and Technology Park D third floor Patentee after: Qingdao Bello Biotechnology Co., Ltd. Address before: 402, room 4, procuratorate dormitory, Lixia District, Jingshan Road, Lixia District, Shandong, Ji'nan, 250000 Patentee before: Wen Xin |
|
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 266012 Shandong province Qingdao City, Hefei Road No. 280 17 Patentee after: Qingdao Bello Biotechnology Co., Ltd. Address before: 266071 Shandong Province, Qingdao city Hongkong Road No. 9 - Qingdao science and Technology Park D third floor Patentee before: Qingdao Bello Biotechnology Co., Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: WEN XIN Free format text: FORMER OWNER: QINGDAO BELLO BIOTECHNOLOGY CO., LTD. Effective date: 20150204 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266012 QINGDAO, SHANDONG PROVINCE TO: 250014 JINAN, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150204 Address after: 402, room 4, procuratorate dormitory, Lixia District, Jingshan Road, Lixia District, Shandong, Ji'nan, 250014 Patentee after: Wen Xin Address before: 266012 Shandong province Qingdao City, Hefei Road No. 280 17 Patentee before: Qingdao Bello Biotechnology Co., Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20120111 |
|
| CX01 | Expiry of patent term |